Surrozen (SRZN) Accounts Payables (2020 - 2026)
Surrozen (SRZN) posted quarterly Accounts Payables of $889000.0 for Q1 2026, up 194.37% year-over-year from $302000.0 in Q1 2025, and up 22.12% quarter-over-quarter from $728000.0 in Q4 2025.
Surrozen (SRZN) Accounts Payables (2020 - 2026) Analysis & Trends
Surrozen's Accounts Payables history runs 7 years deep, the most recent figure standing at $889000.0 for Q1 2026.
- In Q1 2026, Accounts Payables rose 194.37% year-over-year to $889000.0; the TTM figure through Mar 2026 stood at $889000.0 (up 194.37% YoY), while the FY2025 annual figure was $728000.0, up 137.91% from the prior year.
- Accounts Payables for Q1 2026 stood at $889000.0, up from $728000.0 in the prior quarter.
- The five-year high for Accounts Payables was $1.0 million in Q1 2022, with the low at $131000.0 in Q1 2024.
- The 5-year median for Accounts Payables is $354000.0 (2025), against an average of $432294.1.
- The sharpest annual moves came in 2023 and 2026: Accounts Payables slumped 83.64% in 2023, then soared 194.37% in 2026.
- Surrozen's Accounts Payables stood at $658000.0 in 2022, then retreated by 20.21% to $525000.0 in 2023, then tumbled by 41.71% to $306000.0 in 2024, then surged by 137.91% to $728000.0 in 2025, then advanced by 22.12% to $889000.0 in 2026.
- Business Quant data shows SRZN's Accounts Payables at $889000.0 in Q1 2026, $728000.0 in Q4 2025, and $538000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.07 Mn |
| Mar 31, 2026 | 889,000.00 |
| Dec 31, 2025 | 728,000.00 |
| Sep 30, 2025 | 538,000.00 |
| Jun 30, 2025 | 354,000.00 |
| Mar 31, 2025 | 302,000.00 |
| Dec 31, 2024 | 306,000.00 |
| Sep 30, 2024 | 276,000.00 |
| Jun 30, 2024 | 173,000.00 |
| Mar 31, 2024 | 131,000.00 |
| Dec 31, 2023 | 525,000.00 |
| Sep 30, 2023 | 287,000.00 |
| Jun 30, 2023 | 186,000.00 |
| Mar 31, 2023 | 171,000.00 |
| Dec 31, 2022 | 658,000.00 |
| Sep 30, 2022 | 362,000.00 |
| Jun 30, 2022 | 418,000.00 |
| Mar 31, 2022 | 1.05 Mn |
| Dec 31, 2021 | 2.72 Mn |
| Sep 30, 2021 | 1.83 Mn |